InsiderSignal.AI

InsiderSignal.ai

LBRX - Lb Pharmaceuticals Inc

Insider Purchase by Nussbaum Ran (Dir)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

5 months ago, Nussbaum Ran, serving as Dir at Lb Pharmaceuticals Inc (LBRX), purchased 1,000,000 shares at $15.00 per share, for a total transaction value of $15,000,000.00. Following this transaction, Nussbaum Ran now holds 1,411,681 shares of LBRX.

This purchase represents a 243.00% increase in Nussbaum Ran's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, September 12, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, September 16, 2025, 4 days after the trade was made.

Lb Pharmaceuticals Inc operates in the NONE sector, specifically within the NONE industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Nussbaum Ran

Nussbaum Ran

Dir

Ran Nussbaum is a prominent life-sciences investor, aged 52, serving as Managing Partner and Co-Founder of Pontifax, a venture capital firm focused on pharmaceuticals, biotech, and health services with over $370 million under management and more than 65 portfolio companies globally[[1]](https://fintool.com/app/research/companies/KROS/people/ran-nussbaum)[[2]](https://www.streetwisereports.com/pub/htdocs/expert.html?id=9421)[[4]](https://www.evalyze.ai/investors/ran-nussbaum). He currently holds the position of Director at LB Pharmaceuticals Inc (LBRX), where he owns approximately 1,823,362 shares valued at over $36 million, reflecting his recent insider trading activity[[3]](https://www.gurufocus.com/insider/74404/ran-nussbaum)[[6]](https://lbpharma.us/about-us/)[[8]](https://biotechhunter.com/people/ran-nussbaum-10099). Nussbaum's career highlights include prior directorships at numerous public companies such as Keros Therapeutics (2016–2025), ArQule (acquired by Merck), Kite Pharma (acquired by Gilead), Prevail Therapeutics (acquired by Eli Lilly), VBI Vaccines, UroGen Pharma, BioBlast, and Eloxx, showcasing his expertise in guiding firms through strategic exits and governance[[1]](https://fintool.com/app/research/companies/KROS/people/ran-nussbaum)[[5]](https://www.vbivaccines.com/press-releases/vbi-appoints-ran-nussbaum-to-bod/). Before co-founding Pontifax in 2004, he served as CEO of Biomedix, Chairman of NasVax Ltd., and partner at Israel's largest business intelligence firm, emphasizing hands-on strategic oversight in biotech[[2]](https://www.streetwisereports.com/pub/htdocs/expert.html?id=9421)[[7]](https://app.boardroomalpha.com/profiles/people/A1098875-RAN_NUSSBAUM).

View full insider profile →

Trade Price

$15.00

Quantity

1,000,000

Total Value

$15,000,000.00

Shares Owned

1,411,681

Trade Date

Friday, September 12, 2025

163 days ago

SEC Filing Date

Tuesday, September 16, 2025

Filed 4 days after trade

NONENONE

About Lb Pharmaceuticals Inc

Company Overview

No company information available
View news mentioning LBRX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/362422

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime